Cargando…

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

PURPOSE: Glasdegib, an oral inhibitor of the Hedgehog signaling pathway, is approved in the United States in combination with low-dose cytarabine (LDAC) to treat patients with newly diagnosed acute myeloid leukemia (AML) ineligible to receive intensive chemotherapy. This population pharmacokinetic/p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Swan, Shaik, Naveed, Chan, Geoffrey, Cortes, Jorge E., Ruiz-Garcia, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515941/ https://www.ncbi.nlm.nih.gov/pubmed/32885274 http://dx.doi.org/10.1007/s00280-020-04132-x

Ejemplares similares

Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
por: Ruiz‐Garcia, Ana, et al.
Publicado: (2020)

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Cortes, Jorge E., et al.
Publicado: (2018)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
por: Lin, Swan, et al.
Publicado: (2019)

Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
por: Shaik, Naveed, et al.
Publicado: (2021)

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
por: Cortes, Jorge E., et al.
Publicado: (2020)

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
por: Sekeres, Mikkael A., et al.
Publicado: (2023)

Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
por: Thompson, Daniel L., et al.
Publicado: (2020)

Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia
por: Garrett, May, et al.
Publicado: (2023)

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists
por: Relias, Valerie, et al.
Publicado: (2020)

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021)

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
por: Heuser, Michael, et al.
Publicado: (2021)

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2019)

Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies
por: Minami, Yosuke, et al.
Publicado: (2017)

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
por: Heuser, Michael, et al.
Publicado: (2021)

Clinical and Model‐Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018)

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy
por: Solem, Caitlyn T., et al.
Publicado: (2020)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2017)

The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia
por: Park, Yumi, et al.
Publicado: (2018)

Invasive Fungal Disease in Patients with Newly Diagnosed Acute Myeloid Leukemia
por: Wasylyshyn, Anastasia I., et al.
Publicado: (2021)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
por: Cortes, Jorge E., et al.
Publicado: (2018)

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
por: Togasaki, E, et al.
Publicado: (2017)

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
por: Yoo, Kwai Han, et al.
Publicado: (2020)

The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia
por: Liu, Chia‐Jen, et al.
Publicado: (2020)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

PB1842: EARLY DEATH IN NEWLY DIAGNOSED ADULT ACUTE MYELOID LEUKEMIA
por: Siala, N., et al.
Publicado: (2022)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue
por: Peklar, Boris, et al.
Publicado: (2022)

Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall Survival
por: Oyekunle, Anthony A., et al.
Publicado: (2016)

Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival
por: Stabellini, Nickolas, et al.
Publicado: (2022)

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies
por: Kirschner, Martin, et al.
Publicado: (2022)

Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
por: Lim, Ming Y, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4psjumuq71thgg7rc4e2g17g2k